
Opinion|Videos|July 29, 2024
Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection
Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
By Improving Sleep, TNX-102 SL Reduces Pain and Fatigue in Fibromyalgia
2
Gates Foundation, OpenAI Launch $50M AI Health Initiative in Africa
3
FDA Draft Guidance Proposes CR, MRD to Accelerate MM Drug Approval
4
Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care
5





























































